Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy
Pre-treatment <i>MYC</i> amplification and PS were independently associated with clinical outcomes in HER2-positive advanced GC patients treated with first-line trastuzumab plus chemotherapy. Dynamic post-treatment changes in TMB and CIS provide valuable insights into the relationship between therapeutic response and distinct evolutionary trajectories.
Authors
- Daqiang He
- Junrong Yan (ORCID: https://orcid.org/0000-0001-9750-7518)
- Jiqing Si
- Minchi Yuan (ORCID: https://orcid.org/0009-0000-0167-5454)
- Yu Lei
Institutions
- First People's Hospital of Yuhang District (CN)
- First Hospital of Jiaxing (CN)
- Genesee Community College (US)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1080/07853890.2025.2581815
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00